[New Drug Spotlight] Tacabrutideg - A next-generation, oral BTK-targeting protein degrader (PROTAC) for relapsed or refractory CLL/SLL

Tacabrutideg is a next-generation, orally bioavailable small-molecule BTK-targeting proteolysis-targeting chimera (PROTAC) developed by BeOne Medicines.

[New Drug Spotlight] Orforglipron - An oral, non-peptide small-molecule GLP-1 receptor agonist for glycaemic control and chronic weight management

Orforglipron (Foundayo™ (US)) is a next-generation, orally available, non-peptide small-molecule GLP-1 receptor agonist (discovered by Chugai and developed/commercialized by Eli Lilly).

[New Drug Spotlight] Sonrotoclax - A next-generation, oral BCL-2 inhibitor for the treatment of patients with relapsed or refractory CLL/SLL and MCL

Sonrotoclax is a next-generation, highly selective, oral B-cell lymphoma-2 (BCL-2) inhibitor originally developed by BeiGene.

[New Drug Spotlight] Etripamil - A first-in-class, short-acting intranasal L-type calcium-channel blocker for the treatment of PVST

Etripamil is a first-in-class, short-acting intranasal L-type calcium-channel blocker originally developed by Milestone Pharmaceuticals.

[New Drug Spotlight] Aficamten - a next-in-class oral cardiac myosin inhibitor for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM)

Aficamten (brand name Myqorzo) is a next-in-class, oral cardiac myosin inhibitor originally discovered and developed by Cytokinetics.

[New Drug Spotlight] Pimicotinib - a potential “Best-in-Class” oral, selective CSF-1R inhibitor for tenosynovial giant cell tumor (TGCT)

Pimicotinib is an oral small-molecule, highly selective CSF-1R inhibitor developed by Abbisko Therapeutics.

[Commercial Synthesis Spotlight] Process Development of (S)-2-Methylproline for Daridorexant

α-Substituted proline derivatives are widely used in medicinal chemistry, particularly in peptide-based drug discovery and peptidomimetic design.

[New Drug Spotlight] Ceralasertib - an oral ATR inhibitor disrupting DNA damage checkpoint signaling to enhance tumor sensitivity to replication stress and DNA-damaging therapies

Ceralasertib is an oral ATR (ataxia-telangiectasia and Rad3-related) kinase inhibitor developed by AstraZeneca and currently being evaluated in late-stage clinical trials for advanced solid tumors (for example, post-immunotherapy or platinum-treated NSCLC and ovarian cancer).